Creative Medical Tech shares are trading higher after the company announced it received Notice of Allowance from the United States Patent and Trademark Office for a U.S. patent application titled "Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells"

8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Filed: 2026-08-31 AccNo: 0001477932-26-005329 Size: 947 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.

Creative Medical Technology Says All Patients Enrolled And Treated Across ADAPT Trial Of Olastrocel In Chronic Lower Back Pain, Including FDA-Cleared Opioid Expansion Cohort; Trial Moves To Follow-Up And Phase 3 Planning

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report came out 4